In 2025, Betta Pharmaceuticals completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy) and Scope 3 (indirect emissions across the value chain).
Betta Pharmaceuticals has also provided a category-level breakdown for 3 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.
| Metric (tCO2e) | 2025 | 2024 | 2023 | 2022-2019 |
|---|---|---|---|---|
Total Scope 1 | 1,267.74a | 2,023.91a | 2,282.73a | |
Total Scope 2 | ||||
Unspecified Calculation Method | 11,171.77a | 8,459.8a | 10,876.99a | |
Total Scope 3 | 151,301.66a | 114,778.61a | 121,112.9a | |
Total Scope 1 Revenue Intensity (tCO2e/$M) | 2.459a | 5.1075a | 6.6051a |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
In 2025, the total operational greenhouse gas (GHG) emissions of Betta Pharmaceuticals amounted to 12,439.51 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a
Compared to 2024, the total operational greenhouse gas (GHG) emissions of Betta Pharmaceuticals increased by 18.66%, suggesting that the company faced challenges in reducing its emissions from its core operations.a
In 2025, the total Scope 1 emissions of Betta Pharmaceuticals were 1,267.74 metric tons of CO₂ equivalent (tCO₂e).a
Since 2023, Betta Pharmaceuticals's Scope 1 emissions have decreased by 44.46%, reflecting a declining long-term trend in Scope 1 emissions over time.a
Compared to the previous year (2024), Betta Pharmaceuticals's Scope 1 emissions decreased by 37.36%, highlighting the company's efforts to lower direct emissions from assets it owns or controls.a
In 2025, Betta Pharmaceuticals reported Scope 2 greenhouse gas (GHG) emissions of 11,171.77 tCO₂e without specifying the calculation method.a
Since 2023, Betta Pharmaceuticals's Scope 2 greenhouse gas (GHG) emissions (Unspecified Calculation Method) have remained relatively stable, indicating that Betta Pharmaceuticals's emissions have plateaued with no significant change in its energy consumption footprint.a
Compared to the previous year (2024), Betta Pharmaceuticals's Scope 2 emissions (Unspecified Calculation Method) rose by 32.06% in 2025, suggesting that the company faced challenges in reducing emissions from purchased electricity and energya
In 2025, Betta Pharmaceuticals reported its Scope 2 emissions using an unspecified methodology.a
In 2025, Betta Pharmaceuticals reported 151,301.66 metric tons of CO₂ equivalent (tCO₂e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain.a
The 2025 disclosure of Betta Pharmaceuticals includes a breakdown across 3 of the 15 Scope 3 categories defined by the GHG Protocol, matching the level of disclosure in 2024, demonstrating consistent Scope 3 emissions reporting coverage year over year.a
In 2025, Betta Pharmaceuticals reported total Scope 3 emissions of 151,301.66 metric tons of CO₂ equivalent (tCO₂e).a
Approximately 100% of these emissions originated from upstream activities such as purchased goods and capital goods, while 0% came from downstream activities like product use, distribution, and end-of-life treatment.a
Since 2023, Betta Pharmaceuticals's Scope 3 emissions have increased by 24.93%, reflecting a rising long-term trend in Scope 3 emissions over time.a
Compared to the previous year (2024), Betta Pharmaceuticals's Scope 3 emissions increased by 31.82%, suggesting that the company faced challenges in reducing emissions across its value chain.a
In 2025, Betta Pharmaceuticals reported emissions for 3 out of the 15 Scope 3 categories defined by the GHG Protocol.a
The limited disclosure restricts visibility into specific emission sources across the company's value chain.
In 2025, the largest contributors to Betta Pharmaceuticals's Scope 3 emissions were:a
In 2025, Betta Pharmaceuticals reported Scope 1 greenhouse gas (GHG) emissions of 1,267.74 tCO₂e and total revenues of USD 516 millions. This translates into an emissions intensity of 2.46 tCO₂e per millions USD.a
In 2025, Betta Pharmaceuticals reported a Scope 1 emissions intensity of 2.46 tCO₂e per millions USD. Compared to the peer group median of 20.25, this places the company below its industry benchmark, indicating it is more carbon-efficient than most competitors.a
In 2025, Betta Pharmaceuticals ranked 1 out of 24 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a
This places Betta Pharmaceuticals among the top performers, with one of the lowest emissions intensities relative to peers.a
In 2025, Betta Pharmaceuticals reported a total carbon footprint of 163,741.17 metric tons of CO₂ equivalent (tCO₂e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 30.72% increase compared to 2024, suggesting a rise in emissions across its operations or value chain.a
The largest contributor to Betta Pharmaceuticals's total carbon footprint was Scope 3 emissions, accounting for 92.4% of the company's total carbon footprint, followed by Scope 2 emissions at 6.82%.a